AR024472A1 - INHIBITORS OF THE INTEGRIN ALFAV BETA6. - Google Patents
INHIBITORS OF THE INTEGRIN ALFAV BETA6.Info
- Publication number
- AR024472A1 AR024472A1 ARP000103177A ARP000103177A AR024472A1 AR 024472 A1 AR024472 A1 AR 024472A1 AR P000103177 A ARP000103177 A AR P000103177A AR P000103177 A ARP000103177 A AR P000103177A AR 024472 A1 AR024472 A1 AR 024472A1
- Authority
- AR
- Argentina
- Prior art keywords
- ala
- asp
- arg
- phe
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Péptidos de la formula 1, que son biologicamente activos como ligandos de la integrina alfav beta6 Ac-Arg-X1-Asp-X2-X3-X4-X5-X6-NH2 (1) donde Ac significaacetilo, X1 significa Ser, Gly, Thr, Asp, Arg, Val, Tyr, His o Ala, X2 significa Leu, Ile, Nle,Val o Phe, X3 significa Asp, Glu, Lys, Phe, Aib, Nal, Gly, Ala,Bgl o Phg, X4 significa Gly, Ala, Ser, beta-Ala o omega-Abu, X5 significa Leu, Ile, Nle, Val o Phe, X6 significa Arg, Har, Lys, Orn, Phe, Ala, Tyr, Gly, Ser oAsp donde los aminoácidosmen cionados también pueden ser derivatizados los radicales de los aminoácidos están unidos entre sí en forma de péptido por medio delos grupos alfa-amino y alfa-carboxi, están incluidos tanto las formas D como las L de los radicales aminoácidoopticamen te activos, así como sus sales, ydonde queda excluido Ac-Arg-Thr-Asp-Leu-Asp-Ser-Leu-Arg-NH2. Los péptidos de acuerdo con la invencion se pueden aplicar como inhibidores efectivos del receptoralfav beta6 y, por lo tanto, se pueden emplearpara el tra tamiento de diversas enfermedades y estados patologicos.Peptides of formula 1, which are biologically active as ligands of the alpha6 integrin beta6 Ac-Arg-X1-Asp-X2-X3-X4-X5-X6-NH2 (1) where Ac means acetyl, X1 means Ser, Gly, Thr , Asp, Arg, Val, Tyr, His or Ala, X2 means Leu, Ile, Nle, Val or Phe, X3 means Asp, Glu, Lys, Phe, Aib, Nal, Gly, Ala, Bgl or Phg, X4 means Gly , Ala, Ser, beta-Ala or omega-Abu, X5 means Leu, Ile, Nle, Val or Phe, X6 means Arg, Har, Lys, Orn, Phe, Ala, Tyr, Gly, Ser oAsp where amino acids are also linked The amino acid radicals can be derivatized together in the form of a peptide by means of the alpha-amino and alpha-carboxy groups, both D and L forms of the optically active amino acid radicals, as well as their salts, are included, and where Ac-Arg-Thr-Asp-Leu-Asp-Ser-Leu-Arg-NH2 is excluded. The peptides according to the invention can be applied as effective inhibitors of the beta6 receptor and, therefore, can be used for the treatment of various diseases and pathological conditions.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19929410A DE19929410A1 (en) | 1999-06-26 | 1999-06-26 | New octapepide compounds as alpha v beta 6 integrin inhibitors useful for treating and diagnosing heart disease, tumors, osteoporosis, fibrosis, inflammation, infection and psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR024472A1 true AR024472A1 (en) | 2002-10-02 |
Family
ID=7912712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000103177A AR024472A1 (en) | 1999-06-26 | 2000-06-23 | INHIBITORS OF THE INTEGRIN ALFAV BETA6. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1189930A1 (en) |
| JP (1) | JP2003503422A (en) |
| KR (1) | KR20020015704A (en) |
| CN (1) | CN1358195A (en) |
| AR (1) | AR024472A1 (en) |
| AU (1) | AU771099B2 (en) |
| BR (1) | BR0011954A (en) |
| CA (1) | CA2377224A1 (en) |
| CZ (1) | CZ20014484A3 (en) |
| DE (1) | DE19929410A1 (en) |
| HU (1) | HUP0201729A3 (en) |
| MX (1) | MXPA01013247A (en) |
| NO (1) | NO20016341L (en) |
| PL (1) | PL352374A1 (en) |
| SK (1) | SK18722001A3 (en) |
| WO (1) | WO2001000660A1 (en) |
| ZA (1) | ZA200200673B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| JP2007523835A (en) | 2003-02-06 | 2007-08-23 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Peptidesulfonamide |
| GB0520068D0 (en) * | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
| ES2746925T3 (en) | 2006-08-03 | 2020-03-09 | Medimmune Ltd | Antibodies Directed Towards alfaVbeta6 and Use of Them |
| ES2906109T3 (en) | 2016-11-01 | 2022-04-13 | Arrowhead Pharmaceuticals Inc | Alpha-v beta-6 integrin ligands and uses thereof |
| EP3703700A4 (en) | 2017-11-01 | 2021-08-04 | Arrowhead Pharmaceuticals, Inc. | Integrin ligands and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2103139A1 (en) * | 1991-05-14 | 1992-11-15 | George A. Heavner | Peptide inhibitors of inflammation |
| ATE511850T1 (en) * | 1997-08-08 | 2011-06-15 | Univ California | TREATMENT OF BLADDER FIBROSIS WITH ANTIBODIES TO ALPHA-V BETA-6 INTEGRIN |
| CZ20012212A3 (en) * | 1998-12-19 | 2001-09-12 | Merck Patent Gmbh | Peptidic compound, use thereof and pharmaceutical preparation in which the compound is comprised |
-
1999
- 1999-06-26 DE DE19929410A patent/DE19929410A1/en not_active Withdrawn
-
2000
- 2000-06-13 MX MXPA01013247A patent/MXPA01013247A/en unknown
- 2000-06-13 AU AU62630/00A patent/AU771099B2/en not_active Ceased
- 2000-06-13 CA CA002377224A patent/CA2377224A1/en not_active Abandoned
- 2000-06-13 WO PCT/EP2000/005404 patent/WO2001000660A1/en not_active Application Discontinuation
- 2000-06-13 CN CN00809493A patent/CN1358195A/en active Pending
- 2000-06-13 BR BR0011954-7A patent/BR0011954A/en not_active IP Right Cessation
- 2000-06-13 CZ CZ20014484A patent/CZ20014484A3/en unknown
- 2000-06-13 PL PL00352374A patent/PL352374A1/en unknown
- 2000-06-13 HU HU0201729A patent/HUP0201729A3/en unknown
- 2000-06-13 SK SK1872-2001A patent/SK18722001A3/en unknown
- 2000-06-13 JP JP2001507066A patent/JP2003503422A/en active Pending
- 2000-06-13 EP EP00949177A patent/EP1189930A1/en not_active Withdrawn
- 2000-06-13 KR KR1020017016580A patent/KR20020015704A/en not_active Application Discontinuation
- 2000-06-23 AR ARP000103177A patent/AR024472A1/en not_active Application Discontinuation
-
2001
- 2001-12-21 NO NO20016341A patent/NO20016341L/en not_active Application Discontinuation
-
2002
- 2002-01-24 ZA ZA200200673A patent/ZA200200673B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20016341D0 (en) | 2001-12-21 |
| PL352374A1 (en) | 2003-08-25 |
| BR0011954A (en) | 2002-05-07 |
| EP1189930A1 (en) | 2002-03-27 |
| CN1358195A (en) | 2002-07-10 |
| CA2377224A1 (en) | 2001-01-04 |
| MXPA01013247A (en) | 2002-07-02 |
| CZ20014484A3 (en) | 2002-04-17 |
| KR20020015704A (en) | 2002-02-28 |
| SK18722001A3 (en) | 2002-05-09 |
| AU6263000A (en) | 2001-01-31 |
| DE19929410A1 (en) | 2000-12-28 |
| HUP0201729A2 (en) | 2002-08-28 |
| HUP0201729A3 (en) | 2005-01-28 |
| AU771099B2 (en) | 2004-03-11 |
| WO2001000660A1 (en) | 2001-01-04 |
| NO20016341L (en) | 2002-02-25 |
| ZA200200673B (en) | 2003-04-24 |
| JP2003503422A (en) | 2003-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039231A1 (en) | NEW OX40R UNION AGENTS | |
| NL300013I1 (en) | New protein with TNF-inhibiting effect and their ber | |
| CY1105616T1 (en) | PEPTIDE INHIBITORS OF TGFβ1 | |
| ES2160485B1 (en) | INHIBITING PEPTIDES OF NEURONAL EXOCITOSIS, COSMETIC AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| DE60333758D1 (en) | Prevention and reduction of ischemia | |
| DE69435075D1 (en) | , THE SIGNAL SEPENSE PEPTIDES OF THE ENDOPLASMATIC RETICULUM AND AT LEAST ONE OTHER PEPTIDE, THEIR USE IN VACCINES AND THE TREATMENT OF DISEASES | |
| CY1110927T1 (en) | AMINO-CUTTING BRANCHED RANTES AS COMPETENT TO CHEMICALS | |
| DE60331546D1 (en) | USE OF ASPARTIC PROTEASES IN THE FIELDS OF COSMETICS AND TREATMENT | |
| ATE171712T1 (en) | NOVEL KUNITZ-TYPE HUMAN PROTEASE HIBITOR AND CORRESPONDING VARIANTS | |
| DE69009476D1 (en) | INHIBITION OF THE REACTION ROUTE FOR THE N-END RULE IN LIVING CELLS. | |
| AR024472A1 (en) | INHIBITORS OF THE INTEGRIN ALFAV BETA6. | |
| MXPA02000465A (en) | CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN alphaV. | |
| US20080171697A1 (en) | Peptides Having For Example Antiangiogenic Activity and Applications Thereof In Therapeutics | |
| ES2058873T3 (en) | SYNTHETIC PEPTIDIC ANTAGONISTS OF NEUROQUININE A, ITS SALTS AND RESPECTIVE PREPARATION PROCEDURES. | |
| AR020101A1 (en) | A PEPTIDE ANTAGONIST OF THE HUMAN UROQUINASE RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING HIM, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND METHODOPARA TO SELECT AN ADEQUATE PEPTIDE ANTAGONIST. | |
| NO20034146L (en) | Synthetic peptides and method for preventive and therapeutic use in cancer invasion and metastasis | |
| NO20052525D0 (en) | Splice variant of human pituitary growth hormone | |
| DE60120507D1 (en) | HUMAN LEUCINE AREAS REPEATS CONTAINING PROTEIN, PRESENTLY EXPRESSED IN THE THIN DARN, HLRRSI1 | |
| TH57872B (en) | Inhibitors of Intragrin Alpha Nubeta 6 | |
| ATE438660T1 (en) | NEW HUMAN G-PROTEIN COUPLED RECEPTORS AND POLYNUCLEOTIDES CODING THEREFOR | |
| DE60129228D1 (en) | HUMANE 7-TRANSMEMBRANE PROTEINS AND POLYNUCLEOTIDE CODING THEREFOR | |
| RU2022104944A (en) | Recombinant plasmid pBSU-ANQ, providing the synthesis of a recombinant chimeric protein, including a fragment of human angiogenin | |
| TH56074A3 (en) | Alpha v beta 6 inhibitors | |
| ES2119746T3 (en) | NEW PHYSIOLOGICALLY ACTIVE PEPTIDE AND CALCIUM METABOLISM REGULATING AGENT THAT INCLUDES SUCH PEPTIDE AS AN ACTIVE INGREDIENT. | |
| TH56074B (en) | Inhibitor (alpha v beta 6) integrine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |